Several monoclonal anti-SARS-CoV-2 antibodies (mAbs) have received emergency authorization for COVID-19 treatment. However, most of these mAbs are not active against the highly mutated Omicron SARS-CoV-2 subvariants. We have tested a polyclonal approach of equine anti-SARS-CoV-2 F(ab’)2 antibodies that achieved a high level of neutralizing potency against all SARS-CoV-2 VoCs tested including Omicron BA.1, BA.2, BA.2.12 and BA.4/5. A repertoire of antibodies targeting conserved epitopes in different regions of the spike protein could plausibly account for this remarkable breadth of neutralization. These results warrant the clinical investigation of equine polyclonal F(ab’)2 antibodies as a novel therapeutic strategy against COVID-19

中文翻译：

---

多克隆马抗体对 SARS-CoV-2 关注变体的有效中和活性

几种单克隆抗 SARS-CoV-2 抗体 (mAb) 已获得用于 COVID-19 治疗的紧急授权。然而，这些 mAb 中的大多数对高度突变的 Omicron SARS-CoV-2 亚变体没有活性。我们已经测试了马抗 SARS-CoV-2 F(ab')2 抗体的多克隆方法，该方法对所有测试的 SARS-CoV-2 VoC 具有高水平的中和效力，包括 Omicron BA.1、BA.2、BA .2.12 和 BA.4/5。针对刺突蛋白不同区域中保守表位的抗体库可以合理地解释这种显着的中和广度。这些结果支持对马多克隆 F(ab')2 抗体作为针对 COVID-19 的新型治疗策略进行临床研究